Immunomagnetic negative selection from whole blood kit
New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more
Isolate CD4+ T cells directly from human whole blood by immunomagnetic negative selection. Desired cells undergo minimal manipulation and are untouched and highly purified.
This product labels RBCs, platelets and unwanted cells with antibody complexes and magnetic particles. The magnetically labeled RBCs, platelets and non-target cells are separated from the untouched CD4+ T cells in an EasySep™ magnet and poured or pipetted into a new tube.
Isolated cells are available for use in downstream uses such as flow cytometry, functional assays or culture.
• > 99.9% RBC depletion without the need for density gradient centrifugation, sedimentation or lysis
• Up to 96% purity of isolated cells
• Fast, easy-to-use and column-free
• Isolated cells are untouched
EasySep™ Direct Human CD4+ T Cell Isolation Kit (Catalog #19662)
EasySep™ Direct Human CD4+ T Cell Isolation Cocktail, 2 x 2.5 mL
EasySep™ Direct RapidSpheres™, 4 x 2.5 mL
RoboSep™ Human CD4+ T Cell Isolation Kit with Filter Tips (Catalog #19662RF)
EasySep™ Direct Human CD4+ T Cell Isolation Cocktail, 2 x 2.5 mL
EasySep™ Direct: Cell Isolation from Whole Blood in 20 Minutes
Tools For Your Immunology Research
EasySep™ Cell Separation Technology
High-Throughput Immunodensity-Based Cell Subset Isolation Directly from Whole Blood
Human Immune Cytokines
Antigen Processing and Presentation
The Immune Response to HIV Poster
How to Isolate Cells Directly from Whole Blood Using the EasySep™ Purple/Silver Magnets
Isolate Cells with a Simple Pour-Off: EasySep™ Cell Separation Technology
Cell Isolation Directly from Whole Blood without RBC Lysis or Centrifugation: EasySep™ Direct
How to Isolate Cells Directly from Whole Blood Using the Easy 50 EasySep™ Magnet: 30-Minute Protocol
How to Isolate Cells Directly from Whole Blood - EasySep™ Direct Protocol, EasyEights Magnet
Immunomagnetic Cell Isolation of Untouched Lymphocyte Populations Directly from Whole Blood
Load More Educational Materials
Frequently Asked Question
Can EasySep™ be used for either positive or negative selection?
Yes. The EasySep™ kits use either a negative selection approach by targeting and removing unwanted cells or a positive selection approach targeting desired cells. Depletion kits are also available for the removal of cells with a specific undesired marker (e.g. GlyA).
How does the separation work?
Magnetic particles are crosslinked to cells using Tetrameric Antibody Complexes (TAC). When placed in the EasySep™ Magnet, labeled cells migrate to the wall of the tube. The unlabeled cells are then poured off into a separate fraction.
Which columns do I use?
The EasySep™ procedure is column-free. That's right - no columns!
How can I analyze the purity of my enriched sample?
The Product Information Sheet provided with each EasySep™ kit contains detailed staining information.
Can EasySep™ separations be automated?
Yes. RoboSep™, the fully automated cell separator, automates all EasySep™ labeling and cell separation steps.
Can EasySep™ be used to isolate rare cells?
Yes. We recommend a cell concentration of 2x108 cells/mL and a minimum working volume of 100 µL. Samples containing 2x107 cells or fewer should be suspended in 100 µL of buffer.
Are the EasySep™ magnetic particles FACS-compatible?
Yes, the EasySep™ particles are flow cytometry-compatible, as they are very uniform in size and about 5000X smaller than other commercially available magnetic beads used with column-free systems.
Can the EasySep™ magnetic particles be removed after enrichment?
No, but due to the small size of these particles, they will not interfere with downstream applications.
Can I alter the separation time in the magnet?
Yes; however, this may impact the kit's performance. The provided EasySep™ protocols have already been optimized to balance purity, recovery and time spent on the isolation.
For positive selection, can I perform more than 3 separations to increase purity?
Yes, the purity of targeted cells will increase with additional rounds of separations; however, cell recovery will decrease.
How does the binding of the EasySep™ magnetic particle affect the cells? is the function of positively selected cells altered by the bound particles?
Hundreds of publications have used cells selected with EasySep™ positive selection kits for functional studies. Our in-house experiments also confirm that selected cells are not functionally altered by the EasySep™ magnetic particles.
If particle binding is a key concern, we offer two options for negative selection. The EasySep™ negative selection kits can isolate untouched cells with comparable purities, while RosetteSep™ can isolate untouched cells directly from whole blood without using particles or magnets.
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.
Figure 1. Typical EasySep™ Direct Human CD4+ T Cell Isolation Profile
Starting with human whole blood from normal healthy donors, the typical CD4+ T cell (CD3+CD4+) content of the non-lysed final isolated fraction is 93.6 ± 2.5% (gated on CD45) or 93.1 ± 2.5% (not gated on CD45).
In the example above, the CD4+ T cell (CD3+CD4+) content of the lysed whole blood start sample and non-lysed final isolated fraction is 16.5% and 95.8% (gated on CD45), respectively, or 16.3% and 95.1% (not gated on CD45), respectively. The starting frequency of CD4+ T cells in the non-lysed whole blood start sample is 0.016% (data not shown).
Clinical cancer research : an official journal of the American Association for Cancer Research 2019 sep
Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors.
A. Balakrishnan et al.
PURPOSE The outgrowth of antigen-negative variants is a significant challenge for adoptive therapy with T cells that target a single specificity. Chimeric antigen receptors (CAR) are typically designed with one or two scFvs that impart antigen specificity fused to activation and costimulation domains of T-cell signaling molecules. We designed and evaluated the function of CARs with up to three specificities for overcoming tumor escape using Designed Ankyrin Repeat Proteins (DARPins) rather than scFvs for tumor recognition. EXPERIMENTAL DESIGN A monospecific CAR was designed with a DARPin binder (E01) specific for EGFR and compared with a CAR designed using an anti-EGFR scFv. CAR constructs in which DARPins specific for EGFR, EpCAM, and HER2 were linked together in a single CAR were then designed and optimized to achieve multispecific tumor recognition. The efficacy of CAR-T cells bearing a multispecific DARPin CAR for treating tumors with heterogeneous antigen expression was evaluated in vivo. RESULTS The monospecific anti-EGFR E01 DARPin conferred potent tumor regression against EGFR+ targets that was comparable with an anti-EGFR scFv CAR. Linking three separate DARPins in tandem was feasible and in an optimized format generated a single tumor recognition domain that targeted a mixture of heterogeneous tumor cells, each expressing a single antigen, and displayed synergistic activity when tumor cells expressed more than one target antigen. CONCLUSIONS DARPins can serve as high-affinity recognition motifs for CAR design, and their robust architecture enables linking of multiple binders against different antigens to achieve functional synergy and reduce antigen escape.
Science signaling 2018 MAY
Tuning ITAM multiplicity on T cell receptors can control potency and selectivity to ligand density.
J. R. James
The T cell antigen receptor (TCR) recognizes peptides from pathogenic proteins bound in the major histocompatibility complex (MHC). To convert this binding event into downstream signaling, the TCR complex contains immunoreceptor tyrosine-based activation motifs (ITAMs) that act as docking sites for the cytoplasmic tyrosine kinase ZAP-70. Unique among antigen receptors, the TCR complex uses 10 ITAMs to transduce peptide-MHC binding to the cell interior. Using synthetic, drug-inducible receptor-ligand pairs, it was found that greater ITAM multiplicity primarily enhanced the efficiency with which ligand binding was converted into an intracellular signal. This manifested as an increase in the fraction of cells that became activated in response to antigen, and a more synchronous initiation of TCR-proximal signaling, rather than direct amplification of the intracellular signals. Exploiting these findings, the potency and selectivity of chimeric antigen receptors targeted against cancer were substantially enhanced by modulating the number of encoded ITAMs.
Nature genetics 2016 DEC
A genome-wide CRISPR screen identifies a restricted set of HIV host dependency factors.
Park RJ et al.
Host proteins are essential for HIV entry and replication and can be important nonviral therapeutic targets. Large-scale RNA interference (RNAi)-based screens have identified nearly a thousand candidate host factors, but there is little agreement among studies and few factors have been validated. Here we demonstrate that a genome-wide CRISPR-based screen identifies host factors in a physiologically relevant cell system. We identify five factors, including the HIV co-receptors CD4 and CCR5, that are required for HIV infection yet are dispensable for cellular proliferation and viability. Tyrosylprotein sulfotransferase 2 (TPST2) and solute carrier family 35 member B2 (SLC35B2) function in a common pathway to sulfate CCR5 on extracellular tyrosine residues, facilitating CCR5 recognition by the HIV envelope. Activated leukocyte cell adhesion molecule (ALCAM) mediates cell aggregation, which is required for cell-to-cell HIV transmission. We validated these pathways in primary human CD4(+) T cells through Cas9-mediated knockout and antibody blockade. Our findings indicate that HIV infection and replication rely on a limited set of host-dispensable genes and suggest that these pathways can be studied for therapeutic intervention.
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
Contact STEMCELL Technologies
StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not
share your email address with third parties. StemCell Technologies Inc. will use your email address to
confirm your identity and send you newsletters, transaction-related emails, promotional and customer
your email preferences at any time.